Where 10 mg sits in the UK schedule

For adults, 10 mg is one of three named maintenance strengths in the product information. You reach it in stages, when a clinician judges you need more treatment and you have coped with the earlier doses. The schedule does not allow a jump straight from the starting pen to 10 mg.

The same number of milligrams means different things in different medicines. Mounjaro 10 mg does not equal semaglutide 10 mg. A past prescription for another GLP-1 medicine tells you nothing about the right tirzepatide dose. Switching needs its own clinical plan.

What the trial results mean

In SURMOUNT-1, the 10 mg group lost an average of 19.5% of their starting weight at 72 weeks in the treatment-regimen analysis. Participants did not have diabetes and received lifestyle intervention alongside their assigned treatment. The figure covers the whole course for the study group, including the dose increases.

Reaching 10 mg will not bring a further 19.5% loss. Weight lost at the earlier doses forms part of that total. The figure also guarantees no particular difference from 5 mg for you. Trial averages cannot predict how one person responds to one dose change.

Judge the quality of your response

Look beyond the scales. Check whether you can eat a varied diet, drink normally, manage daily activities and keep your strength. Check whether your blood pressure or glucose readings are improving. Note whether you keep needing extra medicines to cope with symptoms. The answers show whether treatment is worthwhile overall.

Weight loss alongside significant weakness, repeated vomiting or too little food and fluid is a problem to report. Someone close to a healthy maintenance range may need a different goal from someone still working towards an agreed first reduction.

Deciding whether to continue or increase

Your clinician considers a higher dose when they expect a worthwhile extra benefit. Finishing a four-week pen does not mean you must go up. If a later increase suits you, it moves through the 12.5 mg step with the minimum intervals set in the label.

Appetite changes during the week, a short plateau or someone else's experience cannot decide the question alone. Review the wider pattern and raise any missed doses, storage worries or injection problems. Each of these affects your response, so sort them out before blaming the dose.

Children and adolescents with type 2 diabetes

The September 2026 UK label includes tirzepatide for type 2 diabetes from age 10, with a maximum of 10 mg in children and adolescents. Adult weight management has a maximum of 15 mg. Adult obesity prescribing advice must never be applied to a child.

For every age group, follow the prescription and the device leaflet. Keep clear notes when your strength changes so you do not use an old pen by mistake alongside the new one. If you are unsure whether a dose went in, never take an extra injection without speaking to your prescribing team.

Sources

Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.

  1. Mounjaro UK Summary of Product Characteristics, updated September 2026 medicines.org.uk
  2. Mounjaro UK patient information leaflet medicines.org.uk
  3. SURMOUNT-1: tirzepatide once weekly for obesity pubmed.ncbi.nlm.nih.gov
  4. NICE: prescribing, reviewing and stopping tirzepatide nice.org.uk

Spotted something out of date? Report a mistake.